Literature DB >> 10930689

An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine.

A M Bennett1, S J Elvin, A J Wright, S M Jones, R J Phillpotts.   

Abstract

The live attenuated vaccine strain of Venezuelan equine encephalitis virus (VEEV), TC-83, protects mice against challenge (subcutaneous and aerosol) with virulent VEEV but is not suitable for widescale human use. Elucidation of the immune response profile of protected mice should assist in the development of an improved vaccine. We determined the optimum dose of TC-83 required to consistently protect Balb/c mice from airborne challenge with the virulent Trinidad Donkey strain of VEEV and studied the development of humoral and cellular immune responses in protected mice between 6 h and 21 days post-vaccination. The most dramatic immune responses occurred in draining lymph nodes 24 h following vaccination with increased levels of activated B cells and T cells of both CD4(+) and CD8(+) subtypes. Activated monocyte/macrophages and natural killer cells were also seen between 6 h and 7 days post-vaccination. Serum contained detectable VEEV-specific IgG on day 5 post-vaccination with titres continuing to rise on days 7, 14 and 21. Isotypes of IgG measured on days 7 and 21 were predominantly of the IgG2a subclass, indicating that the immune response was Th1-mediated. Cytokine mRNA was quantified by RT-PCR and revealed production of the Th1 cytokine IFN-gamma and the inflammatory cytokine TNF-alpha, whereas the Th2 cytokine IL4 was not detected above control levels at any of the time points studied. This data describes key cellular immune responses at early times post-vaccination and is consistent with previous data demonstrating protection against aerosol challenge with VEEV in the absence of detectable levels of specific IgG or IgA antibody.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930689     DOI: 10.1016/s0264-410x(00)00123-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.

Authors:  Marcelo M Samsa; Lesley C Dupuy; Clayton W Beard; Carolyn M Six; Connie S Schmaljohn; Peter W Mason; Andrew J Geall; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-01-07       Impact factor: 11.454

2.  Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization.

Authors:  Daniel R Tonkin; Patricia Jorquera; Tracie Todd; Clayton W Beard; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

3.  A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Authors:  Lesley C Dupuy; Michelle J Richards; Barry Ellefsen; Lillian Chau; Alain Luxembourg; Drew Hannaman; Brian D Livingston; Connie S Schmaljohn
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

4.  Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Patricia Garcia; Erin Jenkins; Pamela J Glass; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

5.  A novel CD8-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5.

Authors:  P M Gray; G D Parks; M A Alexander-Miller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand.

Authors:  Christina C N Wu; Brian Crain; Shiyin Yao; Mojgan Sabet; Fitzgerald S Lao; Rommel I Tawatao; Michael Chan; Donald F Smee; Justin G Julander; Howard B Cottam; Donald G Guiney; Maripat Corr; Dennis A Carson; Tomoko Hayashi
Journal:  J Innate Immun       Date:  2013-11-01       Impact factor: 7.349

7.  Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge.

Authors:  Jennifer L Konopka; Joseph M Thompson; Alan C Whitmore; Drue L Webb; Robert E Johnston
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

8.  Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.

Authors:  Torsten Rülker; Luzie Voß; Philippe Thullier; Lyn M O' Brien; Thibaut Pelat; Stuart D Perkins; Claudia Langermann; Thomas Schirrmann; Stefan Dübel; Hans-Jürgen Marschall; Michael Hust; Birgit Hülseweh
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

9.  Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains.

Authors:  Lyn M O'Brien; Cindy D Underwood-Fowler; Sarah A Goodchild; Amanda L Phelps; Robert J Phillpotts
Journal:  Virol J       Date:  2009-11-19       Impact factor: 4.099

10.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.